A dull first quarter for the pharmaceutical giant Pfizer, whose Q1 2018 results have failed to meet analysts’ expectations. Sales were $12.91bn, that is +1% s Q1 2018, whereas analysts expected $13.14bn. Net income was $3.56bn (vs $3.12bn in Q1 2017), slightly above expectations, as well as EPS ($0.77). During the press conference, Pfizer’s management informed they are still weighing options for the Consumer Health unit ($10bn), after Reckitt Benckiser and GSK have denied interest in the asset. The guidances for the current year have proven incorrect–Pfizer’s shares were 0.85% down in pre-market (Wall Street).